CareDx Inc
NASDAQ:CDNA

Watchlist Manager
CareDx Inc Logo
CareDx Inc
NASDAQ:CDNA
Watchlist
Price: 23.13 USD 2.44% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
CareDx Inc?
Write Note

CareDx Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CareDx Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
CareDx Inc
NASDAQ:CDNA
Total Liabilities & Equity
$477m
CAGR 3-Years
-5%
CAGR 5-Years
27%
CAGR 10-Years
22%
Abbvie Inc
NYSE:ABBV
Total Liabilities & Equity
$143.4B
CAGR 3-Years
-1%
CAGR 5-Years
19%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities & Equity
$54.5B
CAGR 3-Years
-7%
CAGR 5-Years
-2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Liabilities & Equity
$90.9B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities & Equity
$22.2B
CAGR 3-Years
21%
CAGR 5-Years
24%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities & Equity
$37.4B
CAGR 3-Years
17%
CAGR 5-Years
22%
CAGR 10-Years
26%
No Stocks Found

CareDx Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in South San Francisco, California and currently employs 633 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The firm offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its suite of AlloSeq products include AlloSeq Tx, AlloSeq cfDNA, AlloSeq HCT, TruSight HLA, Olerup SSP and QTYPE. The company develops and provides diagnostic surveillance testing services for various transplant recipients.

CDNA Intrinsic Value
16.9 USD
Overvaluation 27%
Intrinsic Value
Price

See Also

What is CareDx Inc's Total Liabilities & Equity?
Total Liabilities & Equity
477m USD

Based on the financial report for Sep 30, 2024, CareDx Inc's Total Liabilities & Equity amounts to 477m USD.

What is CareDx Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
22%

Over the last year, the Total Liabilities & Equity growth was -5%. The average annual Total Liabilities & Equity growth rates for CareDx Inc have been -5% over the past three years , 27% over the past five years , and 22% over the past ten years .

Back to Top